Hims & Hers Health Posts Weak Q2; Heading Into More Near-Term Challenges, Analysts Say

Hims & Hers Health (HIMS) reported Q2 revenue of $544.8 million, missing consensus estimates of $551.7 million, which led to a 4.5% decline in its shares. Despite the company reiterating its 2025 revenue and adjusted EBITDA guidance, analysts expressed concerns over significant near-term headwinds, including an 11.9% sequential contraction in average monthly revenue per subscriber and challenges within its core business, particularly the GLP-1 and sexual health segments, alongside regulatory uncertainties. Analysts also highlighted the complexity and resource demands of the ZAVA acquisition and limited near-term cash flow, tying the company's near-term performance to the uncertain weight loss market dynamics despite planned investments in new categories and international expansion.

Analysis

Hims & Hers Health (HIMS) is facing significant operational and market headwinds despite reiterating its 2025 revenue and adjusted EBITDA guidance. The company reported Q2 revenue of $544.8 million, a miss against the $551.7 million consensus, which prompted a 4.5% decline in its share price. The underlying metrics reveal further weakness, most notably an 11.9% sequential contraction in average monthly revenue per subscriber, which fell to $74. Analysts from BofA Securities and Needham highlight several concerns, including a lack of growth in the core business, which increases the performance burden on the GLP-1 segment. This key weight-loss category is itself surrounded by regulatory uncertainty, which Needham identifies as the primary driver of near-term share performance. Furthermore, the recent ZAVA acquisition is expected to introduce significant regulatory complexity and require substantial resources, while the company's overall investment cycle is limiting near-term cash flow generation. The maintained Underperform and Hold ratings reflect a consensus that these immediate challenges and regulatory questions overshadow the potential long-term benefits from planned expansions into new health categories and markets.

Key Decisions for Investors

• Investors should scrutinize the company's ability to meet its reiterated 2025 guidance given the material 11.9% sequential decline in average revenue per subscriber and noted weakness in the core business.
• The stock's near-term performance is heavily tied to the GLP-1 weight loss segment, so it is critical to monitor for any regulatory developments or shifts in market dynamics in this area.
• Consider the financial drag from the ZAVA acquisition and the company's investment cycle, which are expected to limit near-term cash flow and may present further challenges in the second half of the year.
• Given the cautious analyst ratings and significant operational headwinds, it may be prudent to re-evaluate exposure until there is clear evidence of stabilization in subscriber revenue and a resolution to regulatory uncertainties.